Akero Therapeutics
Restoring Balance. Renewing Life.
74 employees · est. 2017 · South San Francisco, United...
Dewpoint Therapeutics
Translating condensate biology into medicine.
57 employees · est. 2018 · Boston, United States
Akero Therapeutics is the older company (2017 vs 2018).
Side-by-Side Comparison
| Metric | Akero Therapeutics | Dewpoint Therapeutics |
|---|---|---|
| Founded | ||
| Founded | 2017 older | 2018 |
| Headquarters | ||
| Headquarters | South San Francisco, United States | Boston, United States |
| Employees | ||
| Employees | 74 | 57 |
| Industry | ||
| Industry | Biotechnology, Health and Wellness, Life Sciences | Biotechnology, Health Care, Health and Wellness |
| Funding Stage | ||
| Funding Stage | Post Ipo Equity | Series C |
| Total Funding | ||
| Total Funding | Not tracked yet | $287.00M |
| Funding Rounds | ||
| Funding Rounds | 6 | 3 |
| Services | ||
| Services | Not tracked yet | Development of condensate modulating therapies, Preclinical and clinical trials, AI-driven target identification, Integrated drug discovery platform |
| Target Customers | ||
| Target Customers | Not tracked yet | Patients with challenging diseases, Medical researchers, Pharmaceutical companies, Healthcare providers |
| Taxonomy | ||
| Taxonomy | Metabolic Diseases Treatment, NASH Therapy, Clinical-stage Biotech, FGF21 Protein Therapy, Non-alcoholic Steatohepatitis, Liver Disease Treatment, Phase 2b Clinical Trials, Compensated Cirrhosis Therapy, Metabolic Balance Restoration, Fibrosis And Cirrhosis Treatment, Fc Fusion Modified Protein, Pre-cirrhotic MASH Treatment, Serious Metabolic Diseases, Inflammation And Fibrosis Suppression, Meaningful Treatment Options | Biomolecular Condensates, Drug Discovery, Oncology, Neurodegeneration, Cardiopulmonary, Virology, Condensatopathy, Genetically Linked Diseases, Image Analysis, Rare Diseases, Collaboration With Pharmaceutical Partners, Platform Technology, Protein Sequestration Prevention, Biotech Innovation |
| Website | ||
| Website | akerotx.com | dewpointx.com |
About Akero Therapeutics
Akero Therapeutics is a clinical-stage company focused on developing groundbreaking treatments for patients with serious metabolic diseases, particularly MASH, where there is a high unmet medical need. The company's lead product candidate, EFX, is currently undergoing evaluation in the ongoing SYMME...
About Dewpoint Therapeutics
Dewpoint Therapeutics, founded in 2018, stands at the forefront of innovative biotechnology by pioneering the application of biomolecular condensates in drug discovery, a domain previously untapped. With the compelling slogan, "Translating condensate biology into medicine," the company is focused on...
We will tell you when either one moves
BounceWatch watches Akero Therapeutics and Dewpoint Therapeutics for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Akero Therapeutics and Dewpoint Therapeutics — by email.
Frequently Asked Questions
Compare Akero Therapeutics with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at Akero Therapeutics on 9 Jun 2026, and Dewpoint Therapeutics on 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
